ReviewClinical pharmacokinetics2018
Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.
Review in Clinical pharmacokinetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07633626 (Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib), which is not on this map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Inhibition of the serotonin transporter and risk of heart valve disease: A systematic review and meta-analysis.European journal of pharmacology · 2026Pooled it
- Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.The international journal of neuropsychopharmacology · 2021Trial
- Article
- Bioequivalence of a Generic Vortioxetine 20 mg Tablet in Healthy Mexican Volunteers Under Fasting Conditions.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Depression and Suicidality in Patients with Left Ventricular Assist Devices and Advanced Cardiac Therapies: Mechanisms, Risk Factors, and Clinical Management.Medical sciences (Basel, Switzerland) · 2026Review
- Vortioxetine in Subgroups of Patients with Major Depressive Disorder and Early-Stage Dementia: Further Results from the MEMORY Study.Neuropsychiatric disease and treatment · 2026Article
- Comparative effect of vortioxetine and sertraline on clinical and inflammatory profile in Parkinson's disease with comorbid depression.Frontiers in neuroscience · 2026Article
- Green synthesis of silver tungstate/ionic liquid-modified electrode for highly efficient electrochemical detection of the antidepressant Vortioxetine.Scientific reports · 2025Article
- Effects of Short- and Long-Term Vortioxetine Administration on Reproductive Function in Female Rats.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Gestational vortioxetine exposure impairs pregnancy outcomes and fetal brain development via modulation of BDNF/Bax-Bcl2/5-HT pathways in rats.Archives of toxicology · 2025Article
- Vortioxetine Can Be Used Safely to Treat Depression After Implantable Cardioverter Defibrillator Implantation for Congenital Long QT Syndrome: A Case Report.Neuropsychopharmacology reports · 2025Article
- A retrospective analysis of vortioxetine utilization in children and adolescents with major depressive disorder in clinical practice.BMC psychiatry · 2025Article
- Vortioxetine: A Potential Drug for Repurposing for Glioblastoma Treatment via a Microsphere Local Delivery System.ACS biomaterials science & engineering · 2025Article
- Optimizing the diagnosis and treatment of depression in primary care: the emerging role of vortioxetine treatment.Frontiers in psychiatry · 2025Article
- An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics.European journal of drug metabolism and pharmacokinetics · 2025Review
- Therapeutic Drug Monitoring for Individualized Antidepressant Treatment.Drug design, development and therapy · 2025Article
- Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability.Molecular psychiatry · 2024Article
- Analytically Confirmed Intentional Overdose of the Antidepressant Vortioxetine.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses. The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing. The mean absolute oral bioavailability of vortioxetine is 75%. No food effect on pharmacokinetics was observed. Vortioxetine is metabolized by cytochrome P450 enzymes and subsequently by uridine diphosphate glucuronosyltransferase. The major metabolite is pharmacologically inactive, and the minor pharmacologically active metabolite is not expected to cross the blood-brain barrier, making the parent compound primarily responsible for in-vivo activity. No clinically relevant differences were observed in vortioxetine exposure by sex, age, race, body size, and renal or hepatic function. Dose adjustment is only recommended for cytochrome P450 2D6 poor metabolizers based on polymorphism of the cytochrome P450 enzymes involved. Similarly, except for bupropion, a strong cytochrome P450 2D6 inhibitor, and rifampin, a broad cytochrome P450 inducer, co-administration of other drugs evaluated did not affect the vortioxetine exposure or safety profile in any clinically meaningful way. Pharmacodynamic studies demonstrated that vortioxetine achieved high levels of serotonin transporter occupancy in relevant brain areas, affected neurotransmitter levels in the cerebrospinal fluid, and modified abnormal resting state networks in the brain over the therapeutic dose range. Overall, vortioxetine can be administered in most populations studied to date without major dose adjustments; however, dose adjustments should be considered on a patient-by-patient basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.